| P2093 | author name string | Steven Grant | |
| P2860 | cites work | Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage | Q23910280 |
| | Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins | Q24302494 |
| | Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 |
| | BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents | Q24337209 |
| | Death receptor-ligand systems in cancer, cell death, and inflammation | Q26865568 |
| | The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia | Q28075504 |
| | Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1 | Q28256819 |
| | The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 |
| | The pathophysiology of mitochondrial cell death | Q29547893 |
| | Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. | Q30395557 |
| | PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma | Q33409825 |
| | Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. | Q33410225 |
| | MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 |
| | Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia | Q33702409 |
| | Apoptosis of multiple myeloma. | Q33930178 |
| | Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik | Q34056627 |
| | Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. | Q34115920 |
| | Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia | Q34392488 |
| | A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis | Q34398390 |
| | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 |
| | Apoptosis-targeted therapies for cancer | Q35057060 |
| | Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells | Q35153790 |
| | The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells | Q35469548 |
| | Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia | Q35524250 |
| | The BCL-2 family reunion | Q35568029 |
| | Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies | Q35865681 |
| | Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 | Q35920657 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition | Q36169778 |
| | CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies | Q36170136 |
| | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) | Q36349985 |
| | BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. | Q36468244 |
| | Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy | Q36558024 |
| | Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. | Q36625664 |
| | Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells | Q36642752 |
| | MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. | Q36751575 |
| | Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models | Q37045295 |
| | Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins | Q37068553 |
| | High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells | Q37209768 |
| | FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation | Q37460343 |
| | Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer | Q37644600 |
| | Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. | Q38172752 |
| | Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? | Q38193997 |
| | Targeting BCL2 for the treatment of lymphoid malignancies | Q38232485 |
| | Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies | Q38715430 |
| | Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. | Q38722012 |
| | Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma | Q38742685 |
| | BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. | Q38776895 |
| | Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models | Q38789183 |
| | Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax | Q38814114 |
| | Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. | Q38827910 |
| | Venetoclax: First Global Approval | Q38853500 |
| | Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma | Q38896657 |
| | Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia | Q39006397 |
| | BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. | Q39031813 |
| | Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). | Q39065374 |
| | ABT-737 is highly effective against molecular subgroups of multiple myeloma | Q39491434 |
| | Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma | Q40124624 |
| | Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. | Q40127987 |
| | ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. | Q40140803 |
| | Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells | Q42317487 |
| | Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. | Q42399858 |
| | The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma | Q42748426 |
| | The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. | Q44214979 |
| | At the gates of death. | Q50730568 |
| | The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. | Q51014811 |
| | Pathways and mechanisms of venetoclax resistance. | Q51160342 |
| | Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies. | Q52776447 |
| | A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. | Q53595735 |
| | Ripoptosome: a novel IAP-regulated cell death-signalling platform. | Q54547717 |
| | A Bcl-xL timer sets platelet life span | Q80029564 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1292-1299 | |
| P577 | publication date | 2017-08-24 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies | |
| P478 | volume | 59 | |